Sanofi-Aventis debuts prostate cancer drug Jevtana in USA; Genzyme takeover still mooted
Sanofi-Aventis recently announced the launch of its oncology drug, Jevtana (cabazitaxel), in the US. The product launch comes a month after the French drug major gained approval from the US Food and Drug Administration for the use of Jevtana in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) patients who were previously treated with a Taxotere (docetaxel)-containing treatment regimen.
Jevtana's approval came about three months before the official FDA action date of September 2010 (The Pharma Letter June 18). Phase III results showed that treatment with Jevtana in combination with prednisone resulted in a statistically-significant reduction in the risk of death compared to treatment with mitoxantrone and prednisone.
Zacks analysts neutral on Sanofi
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze